Anke Schumann

Dr. Dr. med.
Principal Investigator
(Associated Member)

Center for Pediatrics and Adolescent Medicine
Medical Center – University of Freiburg
Mathildenstr. 1
79106 Freiburg

Current Position

Medical Head of the Laboratory of Clinical Biochemistry and Metabolism, University Children’s Hospital Freiburg
Attending Physician, Research Group Leader

Academic Education

2015-2017 Fellow in the Division of Metabolism, University Children’s Hospital Zurich
2007-2012 Residency in Pediatrics, University Children’s Hospital Heidelberg
1999-2006 Medical School, University Hospital Heidelberg

Advanced Qualifications

2018 Board certification: European Certificate in Pediatric Metabolic Medicine, University Children’s Hospital Zurich
2017 PhD (Dr. sc. nat.), University of Zurich
2012 Board certification: Pediatric and Adolescent Medicine
2007 Doctoral degree in medicine (Dr. med.), University of Heidelberg

Postgraduate Positions

2017 - present Research Group Leader, University Children’s Hospital Freiburg

Link to all publications of Anke Schumann: PubMed

Publications on CRC 1453 funding

Moritz L, Schumann A, Pohl M, Köttgen A, Hannibal L, Ute Spiekerkoetter. A systematic review of metabolomic findings in adult and pediatric renal disease. Clin Biochem (2023). Schumann ASchultheiss UT, Ferreira CR, Blau N. Clinical and biochemical footprints of inherited metabolic diseases. XIV. Metabolic kidney diseases. Mol Genet Metab (2023). Grünert SC, Ziagaki A, Heinen A, Schumann A, Tucci S, Spiekerkoetter U, Schmidts M. Riboflavin 1 Transporter Deficiency: Novel SLC52A1 Variants and Expansion of the Phenotypic Spectrum. Genes (2023). Schumann A, Brutsche M, Havermans M, Grünert SC, Kölker S, Groß O, Hannibal L, Spiekerkoetter U. The impact of metabolic stressors on mitochondrial homeostasis in a renal epithelial cell model of methylmalonic aciduria. Sci Rep (2023). Grünert SC, Matysiak U, Hodde F, Ruzaike G, Lausch E, Schumann A, van der Werf-Grohmann N, Spiekerkoetter U, Schmidts M. Isolated Hypomethylation of IGF2 Associated with Severe Hypoglycemia Responsive to Growth Hormone Treatment. Diagnostics (Basel) (2021).